Axitinib

Active ingredient description

Axitinib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2 and VEGFR-3. These receptors are implicated in pathologic angiogenesis, tumour growth, and metastatic progression of cancer. Axitinib has been shown to potently inhibit VEGF-mediated endothelial cell proliferation and survival.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
L01EK01
Axitinib
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
Discover more medicines within L01EK01

Medicines

Axitinib is the active ingredient of these drugs:

Drug
Countries
INLYTA

Australia Austria Brazil Cyprus France

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
INLYTA Film-coated tablet
Summary of product characteristics (SPC)

Structural formula

Graphic representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

C9LVQ0YUXG - AXITINIB

CAS registry number

319460-85-0 - axitinib

SNOMED-CT

427882000 - Axitinib (substance)

Next: Usage